DXCM News and Press, DexCom Inc. From 06/08/22

Shares of tech stock Amazon officially split this week, and there are more stock splits coming. Many fast-growing companies have been deploying stock splits as a way to bring down their prices and thus be more accessible to a wider pool of investors. Stock splits can also generate some ...

The Nasdaq is falling and in bear market territory. That much is obvious. What may not be so obvious, however, is which stocks on the exchange are likely to bounce back from their steep sell-offs. Many growth stocks on the Nasdaq were trading at inflated premiums for far too long, and a...

The expanded portfolio that includes Dexcom G6 and Dexcom G6 Pro in the U.S. and Dexcom G7 and Dexcom ONE 1 internationally, offers the most innovative, connected and accessible CGM options available for people living with diabetes around the world The portfolio is built...

With CGM now part of the Diabetes Canada Clinical Practice Guidelines, Dexcom CGM use is proven to improve glycemic control 1,2 and can reduce the risk of costly long-term diabetes-related complications compared to fingerstick monitoring. 3 Dexcom, Inc. (...

Shares of DexCom (NASDAQ: DXCM) were jumping 4.5% as of 10:49 a.m. ET on Tuesday after rising as much as 12.4% earlier in the day. The gain came after the company issued a public statement about reports that it's in discussions about a potential merger with Insulet (NASDAQ: PO...

Gainers: TherapeuticsMD (TXMD) +355%. MoonLake Immunotherapeutics (MLTX) +24%. Gritstone bio (GRTS) +18%. Nurix Therapeutics (NRIX) +10%. DexCom (DXCM) +9%. Losers: Outlook Therapeutics (OTLK) -54%. Elevation Oncology (ELEV) -18%. SIGA Technologies (SIGA) -1...

Abbott (NYSE:ABT) announced on Tuesday that the U.S. Food and Drug Administration (FDA) cleared its FreeStyle Libre 3 glucose monitoring system (CGM) for diabetic patients aged four years and older. Welcoming the decision, Jared Watkin, senior vice president of Abbott's (ABT) diabetes care, s...

DexCom (NASDAQ:DXCM) shares surged in the pre-market Tuesday after the medical equipment maker said it was not in active discussions for a merger transaction at the moment. Issuing a statement in response to recent media reports and speculation as well as the upcoming American Diabetes Associ...

DexCom, Inc. (NASDAQ:DXCM) today issued the following statement in response to recent media and market speculation: “Like many companies, Dexcom’s Board and management team regularly review opportunities to enhance stockholder value and create benefits for custom...

Stock valuations are collapsing while earnings are improving, according to Credit Suisse. "While the median company has seen their stock price fall -24.4% since its peak, the median P/E multiple fell -27.5%," strategist Jonathan Golub wrote in a note. "This difference is explained by a health...